Safety and Effects of Ramipril Combined With Candesartan
we hypothesized that combination therapy has additive beneficial effects to improve endothelial dysfunction and adipocytokine profiles in patients with hypertension.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||Cardiovascular and Metabolic Effects of Combination Therapy With Ramipril and Candesartan In Hypertensive Patients|
- comparison of endothelium-dependent dilation among the 3 treatment schemes
|Study Start Date:||August 2003|
|Estimated Study Completion Date:||March 2006|
Forty patients will be given ramipril 10 mg and placebo, ramipril 10 mg and candesartan 16 mg, or candesartan 16 mg and placebo daily in a randomized, double-blind, placebo-controlled cross-over trial with three treatment arms and two washout periods (each 2 months).
Please refer to this study by its ClinicalTrials.gov identifier: NCT00356395
|Principal Investigator:||Kwang K Koh, MD||Cardiology, Gil Heart Center, Gachon Medical School|